Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease

• Elena-Raluca Nicoli ,

  Contributed equally to this work with: Elena-Raluca Nicoli, Nada Al Eisa, Celine V. M. Cluzeau

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• Nada Al Eisa ,

  Contributed equally to this work with: Elena-Raluca Nicoli, Nada Al Eisa, Celine V. M. Cluzeau

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• Celine V. M. Cluzeau ,

  Contributed equally to this work with: Elena-Raluca Nicoli, Nada Al Eisa, Celine V. M. Cluzeau

  Affiliation Section of Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• Christopher A. Wassif,

  Affiliations Department of Pharmacology, University of Oxford, Oxford, United Kingdom, Section of Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• James Gray,

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• Kathryn R. Burkert,

  Affiliation Section of Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• David A. Smith,

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• Lauren Morris,

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• Stephanie M. Cologna,

  Affiliation Section of Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• Cody J. Peer,

  Affiliation Clinical Pharmacology Program, Medical Oncology Branch, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• Tristan M. Sissung,

  Affiliation Clinical Pharmacology Program, Medical Oncology Branch, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• Constantin-Daniel Uscatu,

  Affiliations Department of Pharmacology, University of Oxford, Oxford, United Kingdom, Department of Cellular and Molecular Biology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

  ⨯
• William D. Figg,

  Affiliation Clinical Pharmacology Program, Medical Oncology Branch, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• William J. Pavan,

  Affiliation Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
• Charles H. Vite,

  Affiliation School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Forbes D. Porter ,

  * E-mail: Frances.platt@pharm.ox.ac.uk (FMP); fdporter@mail.nih.gov (FDP)

  Affiliation Section of Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

  ⨯
•  [ ... ],
• Frances M. Platt

  * E-mail: Frances.platt@pharm.ox.ac.uk (FMP); fdporter@mail.nih.gov (FDP)

  Affiliation Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  ⨯
• [ view all ]
• [ view less ]